Shots:
- CareDx has entered a definitive agreement to divest its Lab Products business, incl. PCR & NGS-based transplant diagnostics, to EuroBio Scientific for $170M in cash
- Divestiture aims to streamline operations and refocus on core Precision Medicine Testing Services and digital solutions, while retaining exclusive North America rights to distribute post-transplant monitoring IVD tests, incl. AlloSeq cfDNA
- Expected to close by Q3 2026, proceeds will support CareDx’ long-term growth via investments aligned with its Precision Diagnostics Solutions model, incl. potential inorganic deals, & may also be used for shareholder returns
Ref: Businesswire | Image: CareDx & EuroBio Scientific |Press Release
Related News: Telix Partners with Regeneron to Develop and Commercialize Radiopharmaceutical Therapies for Pain in a ~$2.1B
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
